FI116068B - Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi - Google Patents

Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi Download PDF

Info

Publication number: FI116068B
Authority: FI; Finland
Prior art keywords: vector; gene; arad; seq; plasmid
Prior art date: 2003-09-15

Application number

FI20031319A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI20031319A0 (fi

FI20031319L (fi

Inventor

Mart Ustav

Urve Toots

Andres Maennik

Tanel Tenson

Silja Laht

Maarja Adojaan

Original Assignee

Fit Biotech Oyj Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-15

Filing date

2003-09-15

Publication date

2005-09-15

2003-09-15 Application filed by Fit Biotech Oyj Plc filed Critical Fit Biotech Oyj Plc

2003-09-15 Publication of FI20031319A0 publication Critical patent/FI20031319A0/fi

2003-09-15 Priority to FI20031319A priority Critical patent/FI116068B/fi

2004-09-15 Priority to EP04767054.2A priority patent/EP1664305B1/en

2004-09-15 Priority to US10/531,870 priority patent/US7521182B2/en

2004-09-15 Priority to PL04767054T priority patent/PL1664305T3/pl

2004-09-15 Priority to JP2006526650A priority patent/JP4732348B2/ja

2004-09-15 Priority to AU2004272776A priority patent/AU2004272776B2/en

2004-09-15 Priority to HK06107273.7A priority patent/HK1084975B/en

2004-09-15 Priority to EA200600585A priority patent/EA011823B1/ru

2004-09-15 Priority to ES04767054.2T priority patent/ES2529346T3/es

2004-09-15 Priority to AP2006003577A priority patent/AP1993A/xx

2004-09-15 Priority to CN2004800336943A priority patent/CN1882692B/zh

2004-09-15 Priority to MXPA06002559A priority patent/MXPA06002559A/es

2004-09-15 Priority to NZ545937A priority patent/NZ545937A/xx

2004-09-15 Priority to BRPI0414392-2A priority patent/BRPI0414392A/pt

2004-09-15 Priority to EP14191756.7A priority patent/EP2949753A1/en

2004-09-15 Priority to DK04767054.2T priority patent/DK1664305T3/en

2004-09-15 Priority to PT47670542T priority patent/PT1664305E/pt

2004-09-15 Priority to PCT/FI2004/000540 priority patent/WO2005026364A1/en

2004-09-15 Priority to SI200432219T priority patent/SI1664305T1/sl

2004-09-15 Priority to CA2538863A priority patent/CA2538863C/en

2005-03-16 Publication of FI20031319L publication Critical patent/FI20031319L/fi

2005-09-15 Application granted granted Critical

2005-09-15 Publication of FI116068B publication Critical patent/FI116068B/fi

2006-02-23 Priority to IL173923A priority patent/IL173923A0/en

2006-03-14 Priority to ZA200602153A priority patent/ZA200602153B/en

2006-03-14 Priority to KR1020067005158A priority patent/KR101215245B1/ko

2016-05-05 Priority to HK16105149.1A priority patent/HK1217111A1/en

Links

239000013598 vector Substances 0.000 title claims description 33
230000001580 bacterial effect Effects 0.000 title claims description 28
238000010187 selection method Methods 0.000 title description 2
108090000623 proteins and genes Proteins 0.000 claims description 101
239000013612 plasmid Substances 0.000 claims description 77
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 48
241000588724 Escherichia coli Species 0.000 claims description 31
108020004414 DNA Proteins 0.000 claims description 30
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 28
239000012634 fragment Substances 0.000 claims description 26
239000003550 marker Substances 0.000 claims description 23
230000000295 complement effect Effects 0.000 claims description 22
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 20
239000001963 growth medium Substances 0.000 claims description 18
238000000034 method Methods 0.000 claims description 17
230000010076 replication Effects 0.000 claims description 14
102000004169 proteins and genes Human genes 0.000 claims description 13
230000027455 binding Effects 0.000 claims description 11
108090000416 L-ribulose-5-phosphate 4-epimerases Proteins 0.000 claims description 10
108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
238000004873 anchoring Methods 0.000 claims description 5
239000013604 expression vector Substances 0.000 claims description 5
241000388186 Deltapapillomavirus 4 Species 0.000 claims description 4
241001631646 Papillomaviridae Species 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
101710125507 Integrase/recombinase Proteins 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 60
SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 32
239000002609 medium Substances 0.000 description 28
239000000047 product Substances 0.000 description 25
238000003752 polymerase chain reaction Methods 0.000 description 21
229930027917 kanamycin Natural products 0.000 description 20
229960000318 kanamycin Drugs 0.000 description 20
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 20
229930182823 kanamycin A Natural products 0.000 description 20
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
230000012010 growth Effects 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
238000004519 manufacturing process Methods 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 11
230000008488 polyadenylation Effects 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
230000003115 biocidal effect Effects 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 8
108010048367 enhanced green fluorescent protein Proteins 0.000 description 8
238000000855 fermentation Methods 0.000 description 8
230000004151 fermentation Effects 0.000 description 8
238000000746 purification Methods 0.000 description 8
229940041514 candida albicans extract Drugs 0.000 description 7
230000007774 longterm Effects 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
239000012138 yeast extract Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
108091005904 Hemoglobin subunit beta Proteins 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
101150003725 TK gene Proteins 0.000 description 5
229960000723 ampicillin Drugs 0.000 description 5
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
230000008901 benefit Effects 0.000 description 5
108010006025 bovine growth hormone Proteins 0.000 description 5
238000004520 electroporation Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000006798 recombination Effects 0.000 description 5
238000005215 recombination Methods 0.000 description 5
FNZLKVNUWIIPSJ-UHNVWZDZSA-N D-ribulose 5-phosphate Chemical compound OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHNVWZDZSA-N 0.000 description 4
108010041986 DNA Vaccines Proteins 0.000 description 4
229940021995 DNA vaccine Drugs 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
241000714474 Rous sarcoma virus Species 0.000 description 4
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
239000000306 component Substances 0.000 description 4
230000029087 digestion Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
229960003495 thiamine Drugs 0.000 description 4
235000019157 thiamine Nutrition 0.000 description 4
239000011721 thiamine Substances 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
FNZLKVNUWIIPSJ-UHFFFAOYSA-N Rbl5P Natural products OCC(=O)C(O)C(O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
108700003859 araC Genes Proteins 0.000 description 3
101150044616 araC gene Proteins 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
FNZLKVNUWIIPSJ-RFZPGFLSSA-N D-xylulose 5-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-RFZPGFLSSA-N 0.000 description 2
241000588722 Escherichia Species 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
229920004929 Triton X-114 Polymers 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940126575 aminoglycoside Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000012526 feed medium Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000013642 negative control Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000004108 pentose phosphate pathway Effects 0.000 description 2
238000013492 plasmid preparation Methods 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
108700026220 vif Genes Proteins 0.000 description 2
238000005406 washing Methods 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
FNZLKVNUWIIPSJ-CRCLSJGQSA-N L-ribulose 5-phosphate Chemical compound OCC(=O)[C@@H](O)[C@@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-CRCLSJGQSA-N 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
108091060545 Nonsense suppressor Proteins 0.000 description 1
101150064223 PAG1 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000001937 non-anti-biotic effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000027086 plasmid maintenance Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000007320 rich medium Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
108700017804 supF tRNA Proteins 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229910052714 tellurium Inorganic materials 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

FI20031319A 2003-09-15 2003-09-15 Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi FI116068B (fi)

Priority Applications (24)

Application Number	Priority Date	Filing Date	Title
FI20031319A FI116068B (fi)	2003-09-15	2003-09-15	Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi
NZ545937A NZ545937A (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
EP14191756.7A EP2949753A1 (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
PL04767054T PL1664305T3 (pl)	2003-09-15	2004-09-15	Układ selekcyjny zawierający marker selekcyjny nie oparty na oporności na antybiotyk
JP2006526650A JP4732348B2 (ja)	2003-09-15	2004-09-15	非抗生物質耐性選択マーカー含有選択システム
AU2004272776A AU2004272776B2 (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
HK06107273.7A HK1084975B (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
EA200600585A EA011823B1 (ru)	2003-09-15	2004-09-15	Бактериальная система селекции и ее применение
ES04767054.2T ES2529346T3 (es)	2003-09-15	2004-09-15	Sistema de selección que contiene un marcador de selección que no es de resistencia a antibióticos
AP2006003577A AP1993A (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
CN2004800336943A CN1882692B (zh)	2003-09-15	2004-09-15	包含非抗生素抗性选择标志物的选择系统
MXPA06002559A MXPA06002559A (es)	2003-09-15	2004-09-15	Sistema de seleccion que contiene marcador de seleccion sin resistencia a antibioticos.
EP04767054.2A EP1664305B1 (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
BRPI0414392-2A BRPI0414392A (pt)	2003-09-15	2004-09-15	sistema de seleção contendo um marcador de seleção não antibiótico de resistência
US10/531,870 US7521182B2 (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
DK04767054.2T DK1664305T3 (en)	2003-09-15	2004-09-15	SELECTION SYSTEM CONTAINING NON-ANTIBIOTIC RESISTANCE SELECTION MARKER
PT47670542T PT1664305E (pt)	2003-09-15	2004-09-15	Sistema de seleção contendo um marcador de seleção não antibiótico
PCT/FI2004/000540 WO2005026364A1 (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
SI200432219T SI1664305T1 (sl)	2003-09-15	2004-09-15	Selekcijski sistem, ki vsebuje selekcijski marker ne-rezistenten na antibiotike
CA2538863A CA2538863C (en)	2003-09-15	2004-09-15	Selection system containing non-antibiotic resistance selection marker
IL173923A IL173923A0 (en)	2003-09-15	2006-02-23	Selection system containing non-antibiotic resistance selection marker
ZA200602153A ZA200602153B (en)	2003-09-15	2006-03-14	Selection system containing non-antibiotic resistance selection marker
KR1020067005158A KR101215245B1 (ko)	2003-09-15	2006-03-14	비-항생제 내성 선별 마커를 포함하는 선별 시스템
HK16105149.1A HK1217111A1 (en)	2003-09-15	2016-05-05	Selection system containing non-antibiotic resistance selection marker

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FI20031319		2003-09-15
FI20031319A FI116068B (fi)	2003-09-15	2003-09-15	Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi

Publications (3)

Publication Number	Publication Date
FI20031319A0 FI20031319A0 (fi)	2003-09-15
FI20031319L FI20031319L (fi)	2005-03-16
FI116068B true FI116068B (fi)	2005-09-15

Family

ID=27838984

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI20031319A FI116068B (fi)	2003-09-15	2003-09-15	Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi

Country Status (22)

Country	Link
US (1)	US7521182B2 (xx)
EP (2)	EP1664305B1 (xx)
JP (1)	JP4732348B2 (xx)
KR (1)	KR101215245B1 (xx)
CN (1)	CN1882692B (xx)
AP (1)	AP1993A (xx)
AU (1)	AU2004272776B2 (xx)
BR (1)	BRPI0414392A (xx)
CA (1)	CA2538863C (xx)
DK (1)	DK1664305T3 (xx)
EA (1)	EA011823B1 (xx)
ES (1)	ES2529346T3 (xx)
FI (1)	FI116068B (xx)
HK (1)	HK1217111A1 (xx)
IL (1)	IL173923A0 (xx)
MX (1)	MXPA06002559A (xx)
NZ (1)	NZ545937A (xx)
PL (1)	PL1664305T3 (xx)
PT (1)	PT1664305E (xx)
SI (1)	SI1664305T1 (xx)
WO (1)	WO2005026364A1 (xx)
ZA (1)	ZA200602153B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2684749T3 (es)	2004-08-13	2018-10-04	The Trustees Of The University Of Pennsylvania	Métodos para construir vacunas sin resistencia a antibióticos
US20060135457A1 (en) *	2004-08-13	2006-06-22	Yvonne Paterson	Methods for constructing antibiotic resistance free vaccines
JP5966018B2 (ja) *	2011-12-21	2016-08-10	バイオネット−エイジア，カンパニー・リミテッド	改変ボルデテラ・パータシス株
WO2014018602A1 (en) *	2012-07-26	2014-01-30	Glycos Biotechnologies, Inc.	Strains and methods for plasmid maintenance
EP2950816B1 (en)	2013-02-04	2019-07-31	Schweitzer Biotech Company Ltd.	The use of dna sequences encoding an interferon as vaccine adjuvants
WO2015148680A1 (en)	2014-03-25	2015-10-01	Ginkgo Bioworks, Inc.	Methods and genetic systems for cell engineering
EP3569710A1 (en) *	2018-05-16	2019-11-20	BioVersys AG	Bacterial vectors for genetic manipulation of bacteria
CN109136247B (zh) *	2018-08-09	2022-03-29	天津大学	一种用于铅结合蛋白定向进化的双向筛选系统构建方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5843760A (en) *	1994-04-15	1998-12-01	Midwest Research Institute	Single zymomonas mobilis strain for xylose and arabinose fermentation
KR100445103B1 (ko) *	1994-12-09	2004-12-04	임페리얼 컬리지 이노베이션스 리미티드	유전자의동정
JPH11504218A (ja) *	1995-04-24	1999-04-20	クロマゾームコーポレーション	新規代謝経路の生成およびスクリーニングのための方法
FR2738842B1 (fr)	1995-09-15	1997-10-31	Rhone Poulenc Rorer Sa	Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US6479279B2 (en) *	1995-12-29	2002-11-12	Estonian Biocentre	Episomal vectors and uses thereof
US6162433A (en) *	1996-04-19	2000-12-19	Medeva Europe Limited	Non antibiotic selectable markers for live vaccines
DK0918874T3 (da)	1996-08-16	2001-05-14	Medical Res Council	Selvreplikerende episomale ekspressionsvektorer, som giver vævsspecifik genekspression
US6030807A (en) *	1996-09-10	2000-02-29	The Rockefeller University	Highly regulable promoter for heterologous gene expression
KR100230578B1 (ko) *	1997-07-25	1999-12-01	허영섭	포스포리불로키나제를 융합파트너로 이용하는 재조합 인간 부갑상선호르몬의 발현벡터
US6291245B1 (en) *	1998-07-15	2001-09-18	Roche Diagnostics Gmbh	Host-vector system
US6368793B1 (en) *	1998-10-14	2002-04-09	Microgenomics, Inc.	Metabolic selection methods
CA2404046C (en) *	2000-03-24	2008-06-03	Xoma Technology Ltd.	Improved methods and cells for expression of recombinant protein products
DE60231613D1 (de) *	2001-05-03	2009-04-30	Fit Biotech Oy	Neue expressionsvektoren und deren verwendungen

2003
- 2003-09-15 FI FI20031319A patent/FI116068B/fi not_active IP Right Cessation
2004
- 2004-09-15 US US10/531,870 patent/US7521182B2/en not_active Expired - Fee Related
- 2004-09-15 MX MXPA06002559A patent/MXPA06002559A/es active IP Right Grant
- 2004-09-15 SI SI200432219T patent/SI1664305T1/sl unknown
- 2004-09-15 CN CN2004800336943A patent/CN1882692B/zh not_active Expired - Fee Related
- 2004-09-15 EP EP04767054.2A patent/EP1664305B1/en not_active Expired - Lifetime
- 2004-09-15 DK DK04767054.2T patent/DK1664305T3/en active
- 2004-09-15 BR BRPI0414392-2A patent/BRPI0414392A/pt not_active Application Discontinuation
- 2004-09-15 AP AP2006003577A patent/AP1993A/xx active
- 2004-09-15 JP JP2006526650A patent/JP4732348B2/ja not_active Expired - Fee Related
- 2004-09-15 EP EP14191756.7A patent/EP2949753A1/en not_active Withdrawn
- 2004-09-15 NZ NZ545937A patent/NZ545937A/xx not_active IP Right Cessation
- 2004-09-15 AU AU2004272776A patent/AU2004272776B2/en not_active Ceased
- 2004-09-15 WO PCT/FI2004/000540 patent/WO2005026364A1/en not_active Ceased
- 2004-09-15 PL PL04767054T patent/PL1664305T3/pl unknown
- 2004-09-15 PT PT47670542T patent/PT1664305E/pt unknown
- 2004-09-15 EA EA200600585A patent/EA011823B1/ru not_active IP Right Cessation
- 2004-09-15 ES ES04767054.2T patent/ES2529346T3/es not_active Expired - Lifetime
- 2004-09-15 CA CA2538863A patent/CA2538863C/en not_active Expired - Fee Related
2006
- 2006-02-23 IL IL173923A patent/IL173923A0/en unknown
- 2006-03-14 KR KR1020067005158A patent/KR101215245B1/ko not_active Expired - Fee Related
- 2006-03-14 ZA ZA200602153A patent/ZA200602153B/en unknown
2016
- 2016-05-05 HK HK16105149.1A patent/HK1217111A1/en unknown

Also Published As

Publication number	Publication date
NZ545937A (en)	2008-08-29
EA200600585A1 (ru)	2006-08-25
JP4732348B2 (ja)	2011-07-27
US7521182B2 (en)	2009-04-21
EA011823B1 (ru)	2009-06-30
AU2004272776A1 (en)	2005-03-24
AP1993A (en)	2009-04-09
AU2004272776B2 (en)	2008-11-06
EP2949753A1 (en)	2015-12-02
ZA200602153B (en)	2007-07-25
CA2538863A1 (en)	2005-03-24
KR20060080194A (ko)	2006-07-07
IL173923A0 (en)	2006-07-05
BRPI0414392A (pt)	2006-11-21
SI1664305T1 (sl)	2015-04-30
US20070036822A1 (en)	2007-02-15
JP2007505616A (ja)	2007-03-15
HK1217111A1 (en)	2016-12-23
MXPA06002559A (es)	2006-06-20
CA2538863C (en)	2012-05-29
EP1664305A1 (en)	2006-06-07
CN1882692B (zh)	2012-09-05
DK1664305T3 (en)	2015-02-09
WO2005026364B1 (en)	2005-05-12
AP2006003577A0 (en)	2006-04-30
ES2529346T3 (es)	2015-02-19
EP1664305B1 (en)	2014-11-05
PT1664305E (pt)	2015-02-10
FI20031319A0 (fi)	2003-09-15
HK1084975A1 (en)	2006-08-11
FI20031319L (fi)	2005-03-16
WO2005026364A1 (en)	2005-03-24
KR101215245B1 (ko)	2012-12-24
PL1664305T3 (pl)	2015-04-30
CN1882692A (zh)	2006-12-20

Publication	Publication Date	Title
Dardel et al.	1984	Molecular cloning and primary structure of the Escherichia coli methionyl-tRNA synthetase gene
Nichols et al.	1992	Cloning and sequencing of Escherichia coli ubiC and purification of chorismate lyase
HK1217111A1 (en)	2016-12-23	Selection system containing non-antibiotic resistance selection marker
EP0558631A1 (en)	1993-09-08	Recombinant avirulent salmonella antifertility vaccines
JP3878207B2 (ja)	2007-02-07	ｏｓｍＢプロモータで制御される発現プラスミド
KR20120136349A (ko)	2012-12-18	고가의 화학적 생성물의 미생물 생산, 및 관련 조성물, 방법 및 시스템
WO1999047657A2 (en)	1999-09-23	Lactobacilli harboring aggregation and mucin binding genes as vaccine delivery vehicles
KR20140015136A (ko)	2014-02-06	3-히드록시프로피온산 및 다른 생성물의 제조 방법
Tolmasky et al.	1993	A single amino acid change in AngR, a protein encoded by pJM1-like virulence plasmids, results in hyperproduction of anguibactin
US5434253A (en)	1995-07-18	DNA encoding Helicobacter pylori recombinase
PT1575610E (pt)	2012-03-16	Vacina viva atenuada contra pleuropneumonia porcina
Rule et al.	1985	Overproduction and nucleotide sequence of the respiratory D-lactate dehydrogenase of Escherichia coli
CN100395328C (zh)	2008-06-18	大肠杆菌菌株dsm 6601的无质粒的克隆
FI104429B (fi)	2000-01-31	Ilmentämisplasmidit, jotka sisältävät deo-promoottorin, ja bakteeri-isännät, jotka sisältävät näitä plasmideja
Kawakami et al.	1989	Isolation and characterization of herC, a mutation of Escherichia coli affecting maintenance of ColE1
Heinzen et al.	1995	Characterization of the succinate dehydrogenase-encoding gene cluster (sdh) from the rickettsia Coxiella burnetii
Maas et al.	1995	D-Serine deaminase is a stringent selective marker in genetic crosses
Somarny et al.	2004	Cloning and expression of Vibrio cholerae virulence gene, accessory cholera enterotoxin(ACE)
HK1084975B (en)	2015-08-21	Selection system containing non-antibiotic resistance selection marker
Wachira	1994	Regulation of the Pseudomonas aeruginosa amidase operon by transcription antitermination
CN101497889A (zh)	2009-08-05	人Kappa阿片受体1的制备方法
CN1235053A (zh)	1999-11-17	霍乱弧菌口服活菌苗
MXPA98002798A (en)	1999-05-31	Live attenuated bacteria of the species actinobacillus pleuropneumon

Legal Events

Date	Code	Title	Description
2005-09-15	FG	Patent granted	Ref document number: 116068 Country of ref document: FI
2021-04-29	MM	Patent lapsed

Date

Code

Title

Description